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ABSTRACT 
Lorazepam is commonly prescribed to treat insomnia in depressed patients who receive 
electroconvulsive therapy (ECT); however, lorazepam may interfere with ECT seizure parameters, 
and may thereby compromise the efficacy of the treatment. This study therefore sought to assess 
whether zopicione, a hypnotic agent, interferes less with the ECT seizure. For ethical reasons, the 
study utilized an animal model. Sprague-Dawley rats (n=10/group) received either zopicione (1.5 mg/ 
kg), lorazepam (0.2 mg/kg), or a placebo equivalent. After 30 minutes, an electroconvulsive shock 
was administered to the rats. It was observed that the motor seizure duration but not the total motoric 
phase was significantly attenuated by zopicione. Lorazepam did not impact significantly upon either 
seizure measure. It is concluded that zopicione may be a suitable hypnotic for patients receiving ECT 
only if sufficient time is allowed for the drug to be substantially washed out of the body. 
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Depressed patients who receive 
electroconvulsive therapy (ECT) are frequently 
prescribed lorazepam to treat insomnia; doses 
used range from 1-3 mg nightly (Sackeim et 
al.,1993). The preference for lorazepam is 
possibly due to its relatively short mean half-life 
of 12 hrs, in comparison with 25 hrs for 
nitrazepam and 30 hrs for diazepam 
(Psychotropic Drug Guidelines Subcommittee, 
1995). Since benzodiazepine drugs have 
anticonvulsant properties, a valid concern is that 
the co-prescription of such hypnotic drugs may 
compromise the therapeutic effects of ECT; this 
concern is particularly relevant to ECT with 
unilateral electrode placement (Pettinati et al., 
1990). There is no consensus on the co-
prescription of other agents with sedative 
properties, such as the tricyclic antidepressant 
drugs. On the one hand, the tricyclic drugs may 
augment the antidepressant action of ECT; on 
the other hand, these drugs may unfavourably 
prolong the ECT seizure duration and predispose 
to increased cognitive adverse affects through 
this mechanism and through central 
anticholinergic actions (Andrade,1990; Pritchett 
et al.,1993). 
Zopicione is a cyclopyrrolone hypnotic 
agent which acts on the benzodiazepine-GABA 
receptor complex but not at the same site as the 
benzodiazepine drugs (Byrnes et al.,1992); 
therefore, zopicione may conceivably have a 
lesser impact on the ECT seizure. Furthermore, 
zopicione has a short mean half-life of 5 hours 
(Psychotropic Drug Guidelines Subcommittee, 
1995). Therefore, at the time ECT is 
administered, the drug would have been 
substantially washed out of the body; this could 
further reduce its effects upon the ECT seizure. 
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In view of these conjectures, the present 
study sought to examine the effect of zopiclone 
on one aspect of the ECT seizure , motor seizure 
duration. For ethical reasons, an animal model 
was utilized. 
MATERIAL AND METHOD 
Adult, male, Sprague-Dawley rats were 
housed 3/cage and were provided free access 
to tap water and standard laboratory diet. In each 
cage, rats received zopiclone in solution, 
lorazepam in solution, or distilled water alone. 
Zopiclone was administered in the dose of 1.5 
mg/kg, while lorazepam was administered in the 
dose of 0.2 mg/kg. These doses were selected 
after careful preliminary studies on rats 
demonstrated satisfactory and comparable 
sedation approximately 40 minutes after drug 
administration. These doses also maintained the 
proportion of 7.5 mg (zopiclone) to 1 mg 
(lorazepam); these are the conventional doses 
at which the drugs are prescribed, to the average 
patient, for hypnosis. Both drugs were 
administered by slow, intra-oral syringing, and 
volumes of administration were comparable. 
A single electroconvulsive shock (ECS) 
was administered to each rat using earclip 
electrodes coated with electrode jelly. ECS was 
given 30 minutes after drug administration, using 
the Malar Medisystems (Cochin) constant 
current, unipolar brief-pulse (ECT) device. The 
administered charge was 30 mC, with stimulus 
settings of 0.5A for current intensity, 1 msec for 
pulse width, 60 Hz for pulse frequency, and 1 
sec for stimulus train duration. 
Motor seizure duration was assessed by 
an experienced observer who used a stopwatch. 
The beginning of the seizure was defined as the 
onset of delivery of the ECS stimulus. Two 
definitions of endpoint were employed. The 
endpoint of the motor seizure was defined as 
the termination of synchronous and symmetrical 
convulsive movements; work in our and other 
laboratories has demonstrated that this coincides 
fairly satisfactorily with the endpoint of the EEG 
seizure. The endpoint of the total motoric phase 
was defined as the cessation of all movements; 
this includes a post-ictal phase of random motor 
activity, sometimes termed as the running 
phase' (Fochtmann,1999; personal communi-
cation). While the theoretical significance of the 
running phase remains to be clarified, it is 
emphasized that the rat is unconscious until long 
after both these endpoints are attained. 
RESULTS 
Seizure duration and motoric phase data 
are presented in the table. Nonparametric 
statistical testing was employed because of 
heteroscedasticity of data. The Kruskall-Wallis 
One-Way Analysis of variance found a significant 
difference in mean (ranked) seizure duration 
(X
2=6.67, d.f.=2, p=0.036) but not in motoric 
phase duration (X
2=0.90, d.f.=2, NS). Zopiclone 
significantly attenuated seizure duration but not 
the duration of the motoric phase, while 
lorazepam did not impact upon either measure. 
TABLE 
SEIZURE AND MOTORIC PHASE DURATIONS 
IN RATS RECEIVING ZOPICLONE, LORAZEPAM, 
OR DISTILLED WATER 
Zopiclone 
(17=10) 
Lorazepam 
(17=10) 
Distilled 
water (n=10) 
Seizure duration 
Range 
Mean (s.d.) 
11-25 
14.0(4.2) 
11-47 
18.9(10.9) 
14-38 
20.2(7.8) 
Motoric duration 
Range 
Mean (3d.) 
25-36 
30.4(3.7) 
25-47 
33.2(6.8) 
24-64 
32.9(11.7) 
DISCUSSION 
Agents that abbreviate the ECT seizure 
may impact negatively on the efficacy of ECT; a 
seminal observation was that lidocaine-
abbreviated seizures are subtherapeutic 
(Cronholm & Ottosson,1960). Although it is 
currently realized that seizure duration is not an 
ideal measure of ECT, it is nonetheless the 
measure that is most readily accessible to 
clinicians (Andrade,1997). Bedside 
recommendations for ECT seizure adequacy 
therefore continue to prescribe minimum 
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durations for the motor and/or electroencephalo-
graphic seizures (American Psychiatric 
Association, 1990; Scott & Lock, 1995). 
This study was conducted with the 
expectation that zopiclone might have a lesser 
impact on ECT seizure duration because it does 
not act upon the same site as do the 
benzodiazepine drugs, and because it has not 
been reported to have clinically significant 
anticonvulsant properties (Goa & Heel, 1986). 
However, it was observed that while attenuation 
of seizure duration by lorazepam did not attain 
statistical significance, that with zopiclone did. 
Thus, zopiclone may be even more detrimental 
to ECT efficacy than benzodiazepines. 
These findings were not totally 
unexpected. In animal models, zopiclone was 
shown to inhibit seizures induced by 
electroconvulsive shocks and by 
pentylenetetrazol; the anticonvulsant potency of 
zopiclone in these studies was greater than that 
of chlordiazepoxide and nitrazepam (Julou et 
al.,1983; Goa & Heel,1986). However, no 
literature was available on a direct comparison 
between zopiclone and lorazepam, with 
reference to the seizure duration measures 
addressed in the present investigation. The 
present study was therefore heuristic and 
necessary. 
Neither zopiclone nor lorazepam 
attenuated the total motoric duration. However, 
this phase includes a post-ictal period of random 
motoric movements that bear uncertain 
relevance to the intensity of the ECS seizure 
(Fochtman,1999; personal communication), 
therefore, the absence of impact on the motoric 
phase is of uncertain theoretical importance, but 
nonetheless merits scrutiny in future research. 
From simple, linear, mathematical 
modelling based on drug half-lives, some 
additional considerations are warranted. If ECT 
is scheduled 12 hrs after hypnotic drug treatment, 
approximately 75-85% of the previous night's 
zopiclone dose, and 50% of the previous night's 
lorazepam dose, would have been washed out 
of the body. These considerations apply to 
zopiclone in both single and daily dosing 
situations. With lorazepam, after 2-3 nights of 
treatment, attainment of steady-state levels 
would result in only 35% of the drug being 
washed out by the time the morning's ECT is 
scheduled. It therefore makes sense to prefer 
zopiclone if the scheduling of ECT is such that 
sufficient time has elapsed for zopiclone to have 
been substantially washed out of the body; 
otherwise, lorazepam may remain the hypnotic 
of choice until better alternatives, such as 
Zolpidem, become available in India. 
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